Search results
Results from the WOW.Com Content Network
Affirmed: The guideline was published more than 3 years ago and the recommendations are current, accurate and valid. Review in Progress: The guideline is being assessed for currency or an update is in progress. The status of the guideline and recommended care options may change as a result.
Topics for guidelines are selected on the basis of significant clinical or economic importance; presence of variations in patterns of, or access to, care; availability of suitable data; and ethical considerations. Breast Cancer. Gastrointestinal Cancer.
The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings.
Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines.
Patients with early-stage HER2-negative breast cancer with pathologic invasive residual disease at surgery following standard anthracycline and taxane-based preoperative therapy may be offered up to 6-8 cycles of adjuvant capecitabine.
Breast Cancer Guidance. The American Society of Clinical Oncology offers the following clinical guidance on treatment alternatives during shortages of antineoplastic agents. Decisions should be based on specific goals of the therapy where evidence-based medicine has shown survival outcomes and life-extending benefits in both early and advanced ...
The purpose of this guideline is to develop recommendations concerning the optimal use of systemic neoadjuvant therapy, including chemotherapy, endocrine therapy, and targeted therapy for patients with invasive breast cancer.
The American Society of Clinical Oncology recently published two updated guidelines on issues related to the diagnosis and treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Providers caring for patients with breast cancer with germline BRCA1 / 2 mutations should discuss treatment options related to the index cancer and the increased risk of CBC and new ipsilateral breast cancer.
For patients with hormone receptor (HR)–positive, HER2-negative breast cancer, ASCO recommends the use of neoadjuvant chemotherapy instead of adjuvant chemotherapy but only in patients where a chemotherapy decision can be made without tumor-specific genomic testing and/or surgical pathology data.